January 20, 2026
Don't miss this limited-time offer: Use code JAN2026 to save 50% off a STAT+ annual subscription and unlock unlimited access to our award-winning journalism, premium data tools, event discounts, and more. Thanks for reading!
Samuel Corum/Getty Images

STAT+ | House and Senate appropriators endorse NIH budget increase, reject Trump’s proposed cuts

Trump administration sought 40% cut, but House, Senate negotiators boost NIH spending by $415 million, offer protections on overhead payments

By Anil Oza and Jonathan Wosen


STAT+ | RFK Jr. is moving to remake a little-known vaccine panel. It could have big consequences

RFK Jr. has said that he wants to revamp the vaccine injury compensation system, and reworking the advisory panel could be a first step.

By Chelsea Cirruzzo


STAT+ | What’s in Congress’ sweeping health care deal: PBM reform, telehealth, science funding

Appropriations bill would give HHS $116.8 billion, a modest increase over 2025 but $33 billion more than the Trump administration requested.

By John Wilkerson and Daniel Payne



Illustration: Camille MacMillin/STAT; Photos: Adobe

Is ‘shared decision-making’ being hijacked by U.S. health officials to sow doubt about vaccines?

Trump administration invokes 'shared decision-making' to scale back vaccine guidance, twisting a concept meant to pair evidence with values

By Eric Boodman


Opinion: It’s time to translate vague unease around stem cell IVF into clear guardrails

Stem cells could be used to create eggs and sperm, opening the door to new possibilities — and new ethical conundrums.

By Zubin Master and Scott D. Rhodes


STAT+ | GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal

The centerpiece of the deal is ozureprubart, which is in Phase 2 development as a prophylactic treatment for food allergies.

By Andrew Joseph


Adobe/STAT

STAT+ | Opinion: Excitement and wariness as FDA shifts to much more flexible cell and gene therapy oversight

The new “flexible” CGT oversight system could accelerate development — but it comes with risks for the whole field, and even the FDA itself.

By Paul Knoepfler


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.